Heart failure with preserved ejection fraction and atrial fibrillation: catheter ablation vs. standard medical therapy — a systematic review and meta-analysis

期刊论文
发表日期：

2024年9月15日

查看全文

Mehrdad Mahalleh,
Hamidreza Soleimani,
Mohammadreza Pazoki,
Saba Maleki,
Parham Dastjerdi,
Pouya Ebrahimi,
Sahar Zafarmandi,
Sima Shamshiri Khamene,
Izat Mohammad Khawajah,
Shehroze Tabassum,
Rahul Bhardwaj,
Jishanth Mattumpuram,
Andrew Kaplan,
Marmar Vaseghi,
Parisa Seilani,
Ali Bozorgi,
Kaveh Hosseini,
Stylianos Tzeis

摘要

Background

The latest guidelines advocate for catheter ablation (CA) over standard medical therapy (SMT) for managing atrial fibrillation (AF) in patients with heart failure with reduced ejection fraction (HFrEF). However, significant knowledge gaps exist regarding the effectiveness of CA vs. SMT in patients with heart failure with preserved ejection fraction (HFpEF).

Methods

PubMed, Scopus, and Embase until February 2024 were systematically searched. Given the limited number of randomized studies, propensity score-matched observational studies comparing CA with SMT in AF patients with HFpEF were also included. The primary outcome was a composite endpoint of all-cause mortality and HF hospitalization.

Results

Eight studies that enrolled 17,717 SMT and 2537 CA patients were included. CA was associated with a significantly lower risk of the composite endpoint of all-cause mortality and HF hospitalization (HR 0.61; 95% CI, 0.43–0.85). The risk of HF hospitalization (HR 0.44; 95% CI, 0.23–0.83), cardiovascular mortality (HR 0.43; 95% CI, 0.22–0.84), and AF recurrence (HR 0.53; 95% CI, 0.39–0.73) were also lower in the CA group.

Conclusion

CA demonstrated significant cardiovascular morbidity and mortality benefits compared to SMT in the HFpEF population.